Idorsia presents at J.P. Morgan Healthcare Conference 2025 – fighting to create value for all stakeholders Ad hoc announcement pursuant to Art. 53 LR Presentation to take place on January 15...
Idorsia publishes an invitation to a bondholder meeting Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on February 25, 2025, to vote on proposals to amend the...
Idorsia to call for a bondholder meeting Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that – in the coming days –...
Idorsia provides update on the exclusive negotiations for the global rights to aprocitentan Ad hoc announcement pursuant to Art. 53 LR Company announces delay to the targeted timeline for signing...
Idorsia enters into exclusive negotiations for global rights to aprocitentan Ad hoc announcement pursuant to Art. 53 LR Company enters into exclusive negotiations with an undisclosed party for...
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX:...
Idorsia announces financial results for the first nine months of 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced...
New data on aprocitentan to be presented at the ASN Kidney Week 2024 Allschwil, Switzerland – October 16, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024 Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX:...
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024 Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.